Shingles vaccination is linked to lower heart attack and stroke risk, particularly in high-risk groups, with strongest evidence from observational studies.
Original: This Vaccine is Quietly Doing Something to Your Heart
TL;DR
Observational studies suggest the shingles vaccine may reduce cardiovascular events, but direct causal proof is lacking.
Quick Answer
The shingles vaccine, particularly the older Zostavax and the current Shingrix, is associated with a significantly reduced risk of heart attacks, strokes, and heart failure. Studies tracking over 1.27 million adults found a 23–26% lower risk of major cardiovascular events among vaccinated individuals, with protection lasting up to 8 years. This effect is likely due to the vaccine preventing shingles reactivation, which can cause vascular inflammation and damage. The strongest evidence comes from observational studies and a natural experiment in Wales using birth-date vaccination eligibility.
Claims (10)
1. About 1 in 6 people who receive the recombinant shingles vaccine experience fatigue, headache, or fever, which can interfere with their normal daily activities the next day.
2. People who have had shingles are at a higher risk of having a stroke in the first month after the infection, with this risk gradually decreasing over the next few months and returning to normal levels after one year.
3. People who received the shingles vaccine were observed to have a 20% lower rate of dementia diagnosis over seven years, with this effect being more pronounced in women than in men.
4. People who receive the recombinant shingles vaccine may receive a dementia diagnosis about 164 days later, on average, than those who receive the live attenuated shingles vaccine, with this delay being more pronounced in women.
5. People who receive the shingles vaccine may have a lower risk of developing dementia, and this reduction in risk appears to be greater for women than for men.
6. People who received the shingles vaccine had a lower rate of heart attacks, strokes, and other serious heart problems over eight years compared to those who did not.
7. One type of shingles vaccine, called the recombinant vaccine, reduces the risk of developing shingles more than the older live attenuated vaccine.
8. When the varicella-zoster virus becomes active again, it can cause inflammation in blood vessels, which is associated with a higher likelihood of stroke or heart attack.
9. Two different shingles vaccines, Shingrix and Zostavax, are linked to similar levels of reduction in the risk of cardiovascular events.
10. People who have unhealthy lifestyle habits may experience a stronger reduction in cardiovascular risk after receiving the shingles vaccine compared to those with healthier habits.
Key Takeaways
- •Problem: The shingles virus, which stays dormant after chickenpox, can reactivate and damage blood vessels, increasing the risk of heart attacks, strokes, and heart failure.
- •Core methods: Getting the Shingrix shingles vaccine; getting the older Zostavax shingles vaccine.
- •How methods work: Both vaccines prevent the shingles virus from reactivating, which stops it from causing inflammation in blood vessel walls that can lead to clots and heart problems.
- •Expected outcomes: People who get the vaccine have 23–26% fewer heart attacks, strokes, and heart failure events, with protection lasting up to 8 years.
- •Implementation timeframe: Benefits appear within the first year and last for up to 8 years after vaccination, with CDC recommending vaccination for anyone 50 or older.
Overview
The problem is that shingles reactivation, caused by the varicella-zoster virus, can trigger vascular inflammation leading to heart attacks, strokes, and heart failure. The solution previewed is vaccination with Shingrix or Zostavax, which prevents shingles reactivation and, as multiple observational studies and a natural experiment suggest, reduces cardiovascular risk by 23–26% over up to 8 years. The effect appears stronger in individuals with unhealthy baseline behaviors, suggesting a biological mechanism beyond healthy user bias.
Key Terms
How to Apply
- 1.If you are 50 years or older and have never received a shingles vaccine, schedule an appointment to receive the two-dose Shingrix vaccine series, with the second dose given 2 to 6 months after the first.
- 2.If you previously received the Zostavax vaccine, schedule an appointment to receive the two-dose Shingrix series regardless of how long ago you received Zostavax, as recommended by the CDC.
- 3.Schedule your Shingrix vaccination on a Friday afternoon to allow the most common side effects—such as fatigue, headache, fever, and injection site soreness—to occur over the weekend and minimize disruption to work or daily activities.
- 4.Monitor for side effects after each dose; if you experience fever or fatigue, rest, hydrate, and use over-the-counter pain relievers like acetaminophen or ibuprofen as needed.
Following these steps will reduce your risk of shingles reactivation and associated vascular inflammation, leading to a 23–26% lower risk of heart attacks, strokes, and heart failure over the next 8 years, while also preventing the painful rash and nerve pain caused by shingles.
Studies from Description (7)
Claims (10)
1. About 1 in 6 people who receive the recombinant shingles vaccine experience fatigue, headache, or fever, which can interfere with their normal daily activities the next day.
2. People who have had shingles are at a higher risk of having a stroke in the first month after the infection, with this risk gradually decreasing over the next few months and returning to normal levels after one year.
3. People who received the shingles vaccine were observed to have a 20% lower rate of dementia diagnosis over seven years, with this effect being more pronounced in women than in men.
4. People who receive the recombinant shingles vaccine may receive a dementia diagnosis about 164 days later, on average, than those who receive the live attenuated shingles vaccine, with this delay being more pronounced in women.
5. People who receive the shingles vaccine may have a lower risk of developing dementia, and this reduction in risk appears to be greater for women than for men.
6. People who received the shingles vaccine had a lower rate of heart attacks, strokes, and other serious heart problems over eight years compared to those who did not.
7. One type of shingles vaccine, called the recombinant vaccine, reduces the risk of developing shingles more than the older live attenuated vaccine.
8. When the varicella-zoster virus becomes active again, it can cause inflammation in blood vessels, which is associated with a higher likelihood of stroke or heart attack.
9. Two different shingles vaccines, Shingrix and Zostavax, are linked to similar levels of reduction in the risk of cardiovascular events.
10. People who have unhealthy lifestyle habits may experience a stronger reduction in cardiovascular risk after receiving the shingles vaccine compared to those with healthier habits.
Claims (10)
1. About 1 in 6 people who receive the recombinant shingles vaccine experience fatigue, headache, or fever, which can interfere with their normal daily activities the next day.
2. People who have had shingles are at a higher risk of having a stroke in the first month after the infection, with this risk gradually decreasing over the next few months and returning to normal levels after one year.
3. People who received the shingles vaccine were observed to have a 20% lower rate of dementia diagnosis over seven years, with this effect being more pronounced in women than in men.
4. People who receive the recombinant shingles vaccine may receive a dementia diagnosis about 164 days later, on average, than those who receive the live attenuated shingles vaccine, with this delay being more pronounced in women.
5. People who receive the shingles vaccine may have a lower risk of developing dementia, and this reduction in risk appears to be greater for women than for men.
6. People who received the shingles vaccine had a lower rate of heart attacks, strokes, and other serious heart problems over eight years compared to those who did not.
7. One type of shingles vaccine, called the recombinant vaccine, reduces the risk of developing shingles more than the older live attenuated vaccine.
8. When the varicella-zoster virus becomes active again, it can cause inflammation in blood vessels, which is associated with a higher likelihood of stroke or heart attack.
9. Two different shingles vaccines, Shingrix and Zostavax, are linked to similar levels of reduction in the risk of cardiovascular events.
10. People who have unhealthy lifestyle habits may experience a stronger reduction in cardiovascular risk after receiving the shingles vaccine compared to those with healthier habits.
Related Content
Claims (10)
When the varicella-zoster virus becomes active again, it can cause inflammation in blood vessels, which is associated with a higher likelihood of stroke or heart attack.
People who received the shingles vaccine had a lower rate of heart attacks, strokes, and other serious heart problems over eight years compared to those who did not.
People who received the shingles vaccine were observed to have a 20% lower rate of dementia diagnosis over seven years, with this effect being more pronounced in women than in men.
People who have unhealthy lifestyle habits may experience a stronger reduction in cardiovascular risk after receiving the shingles vaccine compared to those with healthier habits.
People who receive the recombinant shingles vaccine may receive a dementia diagnosis about 164 days later, on average, than those who receive the live attenuated shingles vaccine, with this delay being more pronounced in women.
Studies (7)
The recombinant shingles vaccine is associated with lower risk of dementia
DOI: 10.1038/s41591-024-03201-5
A natural experiment on the effect of herpes zoster vaccination on dementia
DOI: 10.1038/s41586-025-08800-x
A natural experiment on the effect of herpes zoster vaccination on dementia
DOI: 10.1038/s41586-025-08800-x
Coronary flow reserve calculated from pressure measurements in humans. Validation with positron emission tomography.
DOI: 10.1161/01.cir.89.3.1013
Herpes zoster and the risk of ischemic and hemorrhagic stroke: A systematic review and meta-analysis
DOI: 10.1371/journal.pone.0171182